Aurora Cannabis Expands U.K. Medical Cannabis Distribution With £2.1 Million Deal

Key Points

• Aurora acquired 100% of Internode Pharma and HAP Pharma through a wholly owned subsidiary.
• The company paid £2.1 million in cash at closing, subject to certain post-closing conditions.
• Internode Pharma is a licensed U.K. medical-cannabis importer and wholesaler.
• HAP Pharma operates a licensed virtual pharmacy in Birmingham, England.
• Aurora expects the acquisition to add to adjusted EBITDA over future quarters by improving operating efficiency and reducing use of third-party distributors.
• The company did not disclose expected revenue, cost savings, integration expenses, or a specific financial-impact timeline.

Aurora Cannabis Inc. (Nasdaq: ACB) has acquired HAP Pharma Limited and Internode Pharma Limited for £2.1 million in cash, expanding its medical-cannabis distribution capabilities in the United Kingdom. The transaction gives Aurora greater control over importing, wholesaling, pharmacy operations, and delivery to U.K. patients.

 Aurora Gains More Control Over the U.K. Patient Supply Chain

The acquisition brings importation, wholesale distribution, pharmacy fulfillment, and patient delivery under Aurora’s ownership. This gives the company a more direct route from its medical-cannabis cultivation and manufacturing operations to U.K. patients.

Aurora previously relied more heavily on external distribution partners in the U.K. Management believes the acquisition can improve product availability, inventory management, supply-chain reliability, and service for patients and prescribers. The expected benefits will depend on the company’s ability to integrate the businesses, maintain regulatory compliance, and grow patient demand.

U.K. Market Remains a Core European Growth Opportunity

Aurora identifies the United Kingdom as one of Europe’s largest medical-cannabis markets, with a population of approximately 70 million people. The company sees an opportunity to increase its market share as medical-cannabis awareness, prescribing activity, and patient access continue to develop.

The acquired businesses give Aurora an established local platform for importing, distributing, and dispensing medical cannabis. Aurora said it may pursue additional investment in U.K. distribution capacity as demand grows.

However, medical-cannabis growth in the U.K. remains subject to regulation, physician prescribing patterns, patient access, reimbursement, competition, and product availability.

Deal Is Expected to Improve Adjusted EBITDA

Aurora expects the transaction to be accretive to adjusted EBITDA in future quarters. The company attributes the expected benefit to operational efficiencies and reduced dependence on third-party distributors.

Adjusted EBITDA is a non-GAAP measure and does not directly reflect net income, cash flow, or standardized IFRS results. Aurora has not quantified anticipated savings or indicated when investors should expect the acquisition to materially affect earnings.

Acquisition Supports Aurora’s Medical-First International Strategy

Aurora operates medical and consumer cannabis businesses across Canada, Europe, Australia, and New Zealand. Its medical portfolio includes MedReleaf, Pedanios, IndiMed, San Raf, Tasty’s, and Whistler Medical Marijuana Co.

The acquisition expands Aurora’s international medical-cannabis infrastructure and supports its strategy of building vertically integrated distribution channels in key markets. Greater distribution control may help Aurora protect margins and respond more quickly to changes in product demand.

 Investors Will Watch U.K. Growth and Integration Results

For ACB investors, the immediate question is whether the newly acquired import, wholesale, and pharmacy operations can produce stronger U.K. sales and measurable efficiency gains.

Key indicators include U.K. medical-cannabis revenue, adjusted EBITDA contribution, integration costs, patient and prescriber growth, inventory availability, regulatory compliance, and any additional investment in distribution capacity. The £2.1 million acquisition gives Aurora a stronger foothold in the U.K., but long-term value will depend on execution and sustained demand for medical cannabis.